PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Sequencing Solutions, Inc.

USPTO PatentsView assignee record - 273 granted patents across 40 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Explore the portfolio See the ranking
273
Total patents granted
40
CPC technology areas
15.1
Avg claims per patent
+1237%
5-year filing velocity

The verdict

Roche holds 273 US patents across 40 technology areas, rank #1,528 of 50,000 tracked assignees.

#1,528
of 50,000 US assignees by volume
Top 4%
by Innovation Score (59.5/100)
15.1
avg claims per patent
+1237%
filing velocity, last 5 yrs

Portfolio overview

Roche Sequencing Solutions, Inc. has been granted 273 US utility patents between 2017 and 2025, placing Roche Sequencing Solutions, Inc. at rank #1,528 across all assignees tracked by PlainPatent. This portfolio spans 40 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.1 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Roche Sequencing Solutions, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Roche sits between Nabtesco Corporation (273 patents, rank #1,524) and China University Of Mining And Technology (272 patents, rank #1,532) - the closest US assignees by grant volume. The composite Innovation Score of 59.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 254 grants, compared with 19 in the 2015–2019 window, a +1237% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Roche Sequencing Solutions, Inc.'s 15.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 40 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Sequencing Solutions, Inc. against peers pursuing similar technology classes.

Who files at Roche's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Roche holds 273 patents at rank #1,528, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Roche

By rank, the assignees closest to #1,528 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Roche's primary technology class.

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

59 Top 4% higher than 96% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

-200204060 201720182019202020212022202320242025 30
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Roche Sequencing Solutions, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 0.4%
2018 3 1.1%
2019 15 5.5%
2020 39 14.3%
2021 50 18.3%
2022 31 11.4%
2023 54 19.8%
2024 50 18.3%
2025 30 11.0%

Which technologies does Roche Sequencing Solutions, Inc. patent most?

Top 15 of 40 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#1,528

Across all tracked assignees

Innovation Score

59.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Roche Sequencing Solutions, Inc. hold?
Roche Sequencing Solutions, Inc. holds 273 US granted patents filed between 2017 and 2025, spanning 40 technology areas.
What is Roche Sequencing Solutions, Inc.'s Innovation Score?
Roche Sequencing Solutions, Inc. has an Innovation Score of 59.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Roche Sequencing Solutions, Inc. focus on?
Roche Sequencing Solutions, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 212 patents. The company has filed patents in 40 CPC subclasses total.
Is Roche Sequencing Solutions, Inc.'s patent filing rate increasing or decreasing?
Roche Sequencing Solutions, Inc.'s recent filing velocity is +1237% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Roche Sequencing Solutions, Inc.'s patents?
Roche Sequencing Solutions, Inc.'s patents average 15.1 claims each. This falls within the standard range, providing solid legal coverage.
How is the Roche Sequencing Solutions, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Roche's 273 grants land it in the top 4% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Roche ranks #1,528 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.